[268 Pages Report] The global anti-microbial/anti-fungal tests market is expected to reach US$ 2.5 Billion by the end of 2022. Growth in the market is predicted to expand at a CAGR rate of 5.7% and surpass ~US$ 4.5 Billion by 2032. Based on test type, the molecular-based tests led the market with a share of nearly 53.5% in 2021.
| Attributes | Key Insights |
|---|---|
| Anti-microbial/Anti-fungal Tests Market Value 2021 | US$ 2.4 Billion |
| Estimated Market Size 2022 | US$ 2.5 Billion |
| Projected Market Value 2032 | US$ 4.5 Billion |
| CAGR 2022 to 2032 | 5.7% |
| Market Share of Top 5 Countries | 55.0% |
Microorganism screening to create novel antibiotics has been successfully pursued for numerous years by the researcher. Fungus and bacteria often generate antibiotics. Bacteria are consumed in a variety of fields, including agriculture. In the pharmaceutical and veterinary industries, an antimicrobial is a substance that kills or inhibits bacterial growth.
Antibiotics are employed against antifungals, and bacteria are utilized against fungi in these cases. Antimicrobial chemotherapeutic use antimicrobial drugs to combat infection, and antimicrobial prophylaxis uses antimicrobial medicines to prevent infection. Antimicrobial susceptibility tests can help physicians choose the best medicine and dosage for difficult-to-treat infections.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
As per Future Market Insights (FMI), the anti-microbial/anti-fungal tests market was approximately 15.4% of the overall ~US$ 15.6 Billion global rapid testing kits market in 2021. Overall sales in the anti-microbial/anti-fungal tests market surged at a CAGR of 5.6% from 2012 to 2021.
Growth in the market is primarily attributed to the increased prevalence of infectious diseases across the globe. Furthermore, rising rates of surgical site infections and other related issues are propelling sales in the antimicrobial antifungal test market. Further, advancements in biotechnology and in diagnostic procedures are facilitating growth in the market.
As a number of pathogenic bacteria develop antibiotic resistance and novel forms of resistance emerge, healthcare professionals are focusing on antimicrobial susceptibility testing (AST). Minimum inhibitory concentrations (MICs) are provided by a rapid multiplexed AST platform at a reasonable cost, allowing for the rapid determination of effective targeted therapy. This is resulting in shorter hospital stays, fewer laboratory tests, and lower morbidity and mortality, as well as associated healthcare costs.
The market witnessed prolific growth as the use of antibiotics and antifungal skyrocketed. Further, nosocomial bacterial superinfections are more common than community-acquired coinfections. This is particularly among ICU patients and those taking immunosuppressive therapy. On the back of these factors, the global anti-microbial/anti-fungal tests market is expected to grow at a CAGR of 5.7% during the forecast period.
Favorable government initiatives and the development of healthcare infrastructure across the globe is the key factor propelling sales in the global anti-microbial/anti-fungal tests kit market. Advancements in point-of-care (POC) detection methods that enable decentralised, quick, sensitive, low-cost COVID-19 infection diagnostics are spuuring the growth in the market.
Rising awareness by government bodies has positively impacted manufacturers and healthcare service providers. For instance, WAAW was formerly known as World Antibiotic Awareness Week, which is now changed to World Antimicrobial Awareness Week in 2020. This reflects WAAW's expanded scope, which now includes all antimicrobials such as antifungals, antibiotics, antiparasitics, and antivirals.
Principal Consultant
The lack of an innovation culture and stringent regulatory approvals might hamper the demand in the market. In general, healthcare providers and medical workers are risk-averse and resistant to policy reforms. In the realm of in-vitro diagnostics, there have been numerous instances where physicians have been highly reluctant to advance. Furthermore, the administration and organization of diagnostic services may further restrict the market in the forecast period's coming years.
Further, the complexity in interpreting the paradoxical growth phenomenon seen with echinocandins and yeasts (which differs from the trailing effect) and uncertainty for caspofungin testing is due to the molecule's lack of stability in culture media. These factors cumulatively might negatively affect the growth in the anti-microbial/anti-fungal tests market.
Growing Preference for Diagnostic Tests to Boost the Sales
The USA dominated the North American anti-microbial/anti-fungal tests market with a total share of about 89.4% in 2021. Growth in the market is primarily underpinned by the growing preference for diagnostic tests recommended by physicians before any type of treatment. Furthermore, widespread awareness of the adverse effects of particular medications, and patients frequently prefer to be fully diagnosed before seeking treatment.
Rising Prevalence of NIC and Diabetes Mellitus to Facilitate the Growth in China
China held approximately 7.5% share in the global anti-microbial/anti-fungal tests market in 2021, as per FMI. Sales in the market are projected to display growth at a CAGR of 7.1% during the forecast period.
Due to the increased number of immunocompromised individuals, invasive fungal infections (IFIs), especially those caused by uncommon yeasts, are becoming more common. Invasive candidiasis is the key concern with significant morbidity and mortality.
It affects patients of all ages, including those with malignancies, non-immunocompromised (NIC) and HIV-negative immunocompromised (IC) patients, individuals among the severely ill, typically hospitalised to an intensive care unit (ICU), or diagnosed with diabetes mellitus or uncontrolled hyperglycaemia needing invasive mechanical ventilation.
Germany Anti-microbial/Anti-fungal Tests Market to Gain from Rising Incidence of Fungal Infection
Germany is set to exhibit a CAGR growth of nearly 7.1% in the Europe anti-microbial/anti-fungal tests market during the forecast period. Candida glabrata is the second most common fungal infection in Germany, causing candidaemia and invasive candidiasis.
This yeast is known for its quick acquisition of antifungal medication resistance. Furthermore, with the increasing prevalence of chronic and infectious diseases, the ageing population will demand the anti-microbial/anti-fungal tests market.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Molecular-Based Tests to Gain Immense Traction through 2022 & Beyond
Molecular-based tests are expected to lead the market, registering growth at a CAGR of 5.3% during the forecast period. The segment is expected to account for a share of more than 50.0% in the global anti-microbial/anti-fungal tests market. Owing to their factors of increasing susceptibility, minimization of false positive results, better turnaround time, and possesses wide applications.
Based on infection, antimicrobial resistance held a revenue share of 48% in 2021 and is expected to display gradual growth over the forecast period. Antimicrobial resistance (AMR) emerges when fungi, viruses, bacteria, and parasites evolve over a period. Therefore it shows no longer responds to antibiotics treatment, making infections more challenging to treat and increasing the risk of disease spread, major illness, and death. This is expected to fuel revenue growth over the forecast period.
Nearly 2 out of 5 Sales are Contributed by Hospitals
As per FMI, hospitals held the market with the highest share value of 36.9% and are expected to maintain the lead over the upcoming decade. Increasing hospital-acquired infections and increasing inpatient admissions are propelling sales of the overall anti-microbial/anti-fungal tests market.
With several competitors in the anti-microbial/anti-fungal tests market, the overall market is fragmented. To meet consumer demand and expand their customer base, these companies are implementing methods such as mergers and acquisitions, partnerships and collaborations, and new product launches.
| Attribute | Details |
|---|---|
| Estimated Market Size 2022 | US$ 2.5 Billion |
| Projected Market Value 2032 | US$ 4.5 Billion |
| CAGR 2022 to 2032 | 5.7% |
| Forecast Period | 2012 to 2021 |
| Historical Data Available for | 2022 to 2032 |
| Market Analysis | US$ Million for Value |
| Key Regions Covered | North America, Latin America, Europe, South Asia, East Asia, Oceania, and Middle East & Africa |
| Key Countries Covered | USA, Canada, Brazil, Mexico, Argentina, UK, Germany, Italy, Russia, Spain, France, BENELUX, Nordic Countries, India, Thailand, Indonesia, Malaysia, Japan, China, South Korea, Australia, New Zealand, Turkey, GCC Countries, South Africa, and North Africa |
| Key Market Segments Covered | Tests, Infection, End User, and Region |
| Key Companies Profiled |
|
The global anti-microbial/anti-fungal tests market is worth US$ 2.4 Billion in 2021 and is set to expand 1.7X over the next ten years.
The anti-microbial/anti-fungal tests market is expected to reach US$ 4.5 Billion by the end of 2032, with sales revenue expected to register a 5.7% CAGR.
The growing geriatric population and innovative product development, increasing prevalence of antimicrobial resistance cases are some of the key trends in this market.
USA, India, China, Germany, and Japan are expected to drive demand for the anti-microbial/anti-fungal tests industry.
North America is one of the key markets for anti-microbial/anti-fungal tests, with the USA accounting for about 89.4% of the North American anti-microbial/anti-fungal tests market in the year 2021.
Demand for anti-microbial/anti-fungal tests in Europe is expected to register a growth of 5.0% CAGR over the next ten years.
Demand for anti-microbial/anti-fungal tests in MEA is expected to register a growth of 4.5% over the next ten years.
China and the USA, Germany are the key producers of anti-microbial/anti-fungal tests.
Abbott Laboratories, bioMérieux SA, Bio-Rad Laboratories Inc., Bruker Corporation, Danaher Corporation, Erba Mannheim, F. Hoffmann-La Roche AG, Luminex Corporation, Meridian Bioscience Inc., Norgen Biotek Corp., Omega Diagnostics Group Plc., Qiagen N.V., Quidel Corporation, and Thermo Fisher Scientific Inc., are some of the key players in the anti-microbial/anti-fungal tests industry.
1. Executive Summary | Anti-microbial/Anti-fungal Tests Market
1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply Side Trends
1.4. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
2.3. Inclusions and Exclusions
3. Key Market Trends
3.1. Key Trends Impacting the Market
3.2. Product Innovation / Development Trends
4. Key Success Factors
4.1. Epidemiology of Key Indication, By Region
4.2. Key Promotional Strategies
4.3. Patient Journey
4.4. Regulatory Scenario
4.5. Reimbursement Landscape
4.6. PESTEL analysis
4.7. Porter’s analysis
4.8. Value Chain
5. Market Background
5.1. Macro-Economic Factors
5.1.1. Global GDP Growth Outlook
5.1.2. Global Healthcare GDP Growth Overview
5.2. Forecast Factors - Relevance & Impact
5.2.1. Rising Prevalence of infectious diseases.
5.2.2. Increasing Awareness and Adoption.
5.2.3. Increase in rapid diagnostics tests.
5.2.4. Increasing prevalence of antimicrobial resistance patients.
5.3. Market Dynamics
5.3.1. Drivers
5.3.2. Restraints
5.3.3. Opportunity Analysis
5.4. Global Supply Demand Analysis
6. COVID-19 Crisis - Crisis Analysis
6.1. COVID-19 and Impact Analysis
6.2. 2021 Market Scenario
6.2.1. By Tests Type
6.2.2. By Infection Type
6.2.3. By End User
6.2.4. By Region
7. Global Market Demand (in Value or Size in US$ Million) Analysis 2012 to 2021 and Forecast, 2022 to 2032
7.1. Historical Market Value (US$ Million) Analysis, 2012 to 2021
7.2. Current and Future Market Value (US$ Million) Projections, 2022 to 2032
7.2.1. Y-o-Y Growth Trend Analysis
7.2.2. Absolute $ Opportunity Analysis
8. Global Market Analysis 2012 to 2021 and Forecast 2022 to 2032, By Tests Type
8.1. Introduction / Key Findings
8.2. Historical Market Size (US$ Million) Analysis By Tests Type, 2012 to 2021
8.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Tests Type, 2022 to 2032
8.3.1. Molecular-Based Tests
8.3.1.1. PCR Test
8.3.1.2. DNA Microarray
8.3.2. Phenotypic Resistance Tests
8.3.3. Complex Test Panels
8.3.4. Mass Spectrometry
8.3.5. Rapid Diagnostic Tests
8.3.5.1. E-Test Antibiotic/Antifungal Strips
8.3.5.2. Biosensor Platforms
8.4. Market Attractiveness Analysis By Tests Type
9. Global Market Analysis 2012 to 2021 and Forecast 2022 to 2032, By Infection Type
9.1. Introduction / Key Findings
9.2. Historical Market Size (US$ Million) Analysis, By Infection Type, 2012 to 2021
9.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Infection Type, 2022 to 2032
9.3.1. Antimicrobial Resistance
9.3.1.1. Methicillin-Resistant Staphylococcus Aureus
9.3.1.2. Vancomycin-Resistant Enterococcus
9.3.1.3. Multi-Drug-Resistant Mycobacterium tuberculosis
9.3.1.4. Carbapenem-Resistant Enterobacteriaceae gut bacteria
9.3.2. Microbial Infection
9.3.3. Antifungal Resistance
9.3.3.1. Candida infections
9.3.3.2. Aspergillus infection
9.3.3.3. Fusariosis
9.3.3.4. Others
9.3.4. Fungal Infection
9.4. Market Attractiveness Analysis By Infection Type
10. Global Market Analysis 2012 to 2021 and Forecast 2022 to 2032, By End User
10.1. Introduction / Key Findings
10.2. Historical Market Size (US$ Million) Analysis, By End User, 2012 to 2021
10.3. Current and Future Market Size (US$ Million) Analysis Forecast By End User, 2022 to 2032
10.3.1. Hospitals
10.3.2. Ambulatory Surgical Centers
10.3.3. Clinics
10.3.4. Community Health Centers
10.3.5. Reference Laboratories
10.4. Market Attractiveness Analysis By End User
11. Global Market Analysis 2012 to 2021 and Forecast 2022 to 2032, by Region
11.1. Introduction
11.2. Historical Market Size (US$ Million) Analysis By Region, 2012 to 2021
11.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Region, 2022 to 2032
11.3.1. North America
11.3.2. Latin America
11.3.3. Europe
11.3.4. East Asia
11.3.5. South Asia
11.3.6. Oceania
11.3.7. Middle East and Africa (MEA)
11.4. Market Attractiveness Analysis By Region
12. North America Market Analysis 2012 to 2021 and Forecast 2022 to 2032
12.1. Introduction
12.2. Historical Market Size (US$ Million) Analysis Trend Analysis By Market Taxonomy, 2012 to 2021
12.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2022 to 2032
12.3.1. By Country
12.3.1.1. United States of America
12.3.1.2. Canada
12.3.2. By Tests Type
12.3.3. By Infection Type
12.3.4. By End User
12.4. Market Attractiveness Analysis
12.4.1. By Country
12.4.2. By Tests Type
12.4.3. By Infection Type
12.4.4. By End User
12.5. Market Trends
12.6. Key Market Participants - Intensity Mapping
12.7. Drivers and Restraints - Impact Analysis
12.8. Country-Level Analysis & Forecast
12.8.1. USA Market Analysis
12.8.1.1. Introduction
12.8.1.2. Market Analysis and Forecast by Market Taxonomy
12.8.1.2.1. By Tests Type
12.8.1.2.2. By Infection Type
12.8.1.2.3. By End User
12.8.2. Canada Market Analysis
12.8.2.1. Introduction
12.8.2.2. Market Analysis and Forecast by Market Taxonomy
12.8.2.2.1. By Tests Type
12.8.2.2.2. By Infection Type
12.8.2.2.3. By End User
13. Latin America Market Analysis 2012 to 2021 and Forecast 2022 to 2032
13.1. Introduction
13.2. Historical Market Size (US$ Million) Analysis Trend Analysis By Market Taxonomy, 2012 to 2021
13.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2022 to 2032
13.3.1. By Country
13.3.1.1. Mexico
13.3.1.2. Brazil
13.3.1.3. Argentina
13.3.1.4. Rest of Latin America
13.3.2. By Tests Type
13.3.3. By Infection Type
13.3.4. By End User
13.4. Market Attractiveness Analysis
13.4.1. By Country
13.4.2. By Tests Type
13.4.3. By Infection Type
13.4.4. By End User
13.5. Market Trends
13.6. Key Market Participants - Intensity Mapping
13.7. Drivers and Restraints - Impact Analysis
13.8. Country-Level Analysis & Forecast
13.8.1. Mexico Market Analysis
13.8.1.1. Introduction
13.8.1.2. Market Analysis and Forecast by Market Taxonomy
13.8.1.2.1. By Tests Type
13.8.1.2.2. By Infection Type
13.8.1.2.3. By End User
13.8.2. Brazil Market Analysis
13.8.2.1. Introduction
13.8.2.2. Market Analysis and Forecast by Market Taxonomy
13.8.2.2.1. By Tests Type
13.8.2.2.2. By Infection Type
13.8.2.2.3. By End User
13.8.3. Argentina Market Analysis
13.8.3.1. Introduction
13.8.3.2. Market Analysis and Forecast by Market Taxonomy
13.8.3.2.1. By Tests Type
13.8.3.2.2. By Infection Type
13.8.3.2.3. By End User
14. Europe Market Analysis 2012 to 2021 and Forecast 2022 to 2032
14.1. Introduction
14.2. Historical Market Size (US$ Million) Analysis Trend Analysis By Market Taxonomy, 2012 to 2021
14.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2022 to 2032
14.3.1. By Country
14.3.1.1. Germany
14.3.1.2. Italy
14.3.1.3. France
14.3.1.4. United Kingdom
14.3.1.5. Spain
14.3.1.6. BENELUX
14.3.1.7. Russia
14.3.1.8. Rest of Europe
14.3.2. By Tests Type
14.3.3. By Infection Type
14.3.4. By End User
14.4. Market Attractiveness Analysis
14.4.1. By Country
14.4.2. By Tests Type
14.4.3. By Infection Type
14.4.4. By End User
14.5. Market Trends
14.6. Key Market Participants - Intensity Mapping
14.7. Drivers and Restraints - Impact Analysis
14.8. Country-Level Analysis & Forecast
14.8.1. Germany Market Analysis
14.8.1.1. Introduction
14.8.1.2. Market Analysis and Forecast by Market Taxonomy
14.8.1.2.1. By Tests Type
14.8.1.2.2. By Infection Type
14.8.1.2.3. By End User
14.8.2. Italy Market Analysis
14.8.2.1. Introduction
14.8.2.2. Market Analysis and Forecast by Market Taxonomy
14.8.2.2.1. By Tests Type
14.8.2.2.2. By Infection Type
14.8.2.2.3. By End User
14.8.3. France Market Analysis
14.8.3.1. Introduction
14.8.3.2. Market Analysis and Forecast by Market Taxonomy
14.8.3.2.1. By Tests Type
14.8.3.2.2. By Infection Type
14.8.3.2.3. By End User
14.8.4. UK Market Analysis
14.8.4.1. Introduction
14.8.4.2. Market Analysis and Forecast by Market Taxonomy
14.8.4.2.1. By Tests Type
14.8.4.2.2. By Infection Type
14.8.4.2.3. By End User
14.8.5. Spain Market Analysis
14.8.5.1. Introduction
14.8.5.2. Market Analysis and Forecast by Market Taxonomy
14.8.5.2.1. By Tests Type
14.8.5.2.2. By Infection Type
14.8.5.2.3. By End User
14.8.6. BENELUX Market Analysis
14.8.6.1. Introduction
14.8.6.2. Market Analysis and Forecast by Market Taxonomy
14.8.6.2.1. By Tests Type
14.8.6.2.2. By Infection Type
14.8.6.2.3. By End User
14.8.7. Russia Market Analysis
14.8.7.1. Introduction
14.8.7.2. Market Analysis and Forecast by Market Taxonomy
14.8.7.2.1. By Tests Type
14.8.7.2.2. By Infection Type
14.8.7.2.3. By End User
15. South Asia Market Analysis 2012 to 2021 and Forecast 2022 to 2032
15.1. Introduction
15.2. Historical Market Size (US$ Million) Analysis Trend Analysis By Market Taxonomy, 2012 to 2021
15.3. Current and Future Market Size (US$ Million) Analysis Forecast By Market Taxonomy, 2022 to 2032
15.3.1. By Country
15.3.1.1. India
15.3.1.2. Indonesia
15.3.1.3. Malaysia
15.3.1.4. Thailand
15.3.1.5. Rest of South Asia
15.3.2. By Tests Type
15.3.3. By Infection Type
15.3.4. By End User
15.4. Market Attractiveness Analysis
15.4.1. By Country
15.4.2. By Tests Type
15.4.3. By Infection Type
15.4.4. By End User
15.5. Market Trends
15.6. Key Market Participants - Intensity Mapping
15.7. Drivers and Restraints - Impact Analysis
15.8. Country-Level Analysis & Forecast
15.8.1. India Market Analysis
15.8.1.1. Introduction
15.8.1.2. Market Analysis and Forecast by Market Taxonomy
15.8.1.2.1. By Tests Type
15.8.1.2.2. By Infection Type
15.8.1.2.3. By End User
15.8.2. Indonesia Market Analysis
15.8.2.1. Introduction
15.8.2.2. Market Analysis and Forecast by Market Taxonomy
15.8.2.2.1. By Tests Type
15.8.2.2.2. By Infection Type
15.8.2.2.3. By End User
15.8.3. Malaysia Market Analysis
15.8.3.1. Introduction
15.8.3.2. Market Analysis and Forecast by Market Taxonomy
15.8.3.2.1. By Tests Type
15.8.3.2.2. By Infection Type
15.8.3.2.3. By End User
15.8.4. Thailand Market Analysis
15.8.4.1. Introduction
15.8.4.2. Market Analysis and Forecast by Market Taxonomy
15.8.4.2.1. By Tests Type
15.8.4.2.2. By Infection Type
15.8.4.2.3. By End User
16. East Asia Market Analysis 2012 to 2021 and Forecast 2022 to 2032
16.1. Introduction
16.2. Historical Market Size (US$ Million) Analysis Trend Analysis By Market Taxonomy, 2012 to 2021
16.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2022 to 2032
16.3.1. By Country
16.3.1.1. China
16.3.1.2. Japan
16.3.1.3. South Korea
16.3.2. By Tests Type
16.3.3. By Infection Type
16.3.4. By End User
16.4. Market Attractiveness Analysis
16.4.1. By Country
16.4.2. By Tests Type
16.4.3. By Infection Type
16.4.4. By End User
16.5. Market Trends
16.6. Key Market Participants - Intensity Mapping
16.7. Drivers and Restraints - Impact Analysis
16.8. Country-Level Analysis & Forecast
16.8.1. China Market Analysis
16.8.1.1. Introduction
16.8.1.2. Market Analysis and Forecast by Market Taxonomy
16.8.1.2.1. By Tests Type
16.8.1.2.2. By Infection Type
16.8.1.2.3. By End User
16.8.2. Japan Market Analysis
16.8.2.1. Introduction
16.8.2.2. Market Analysis and Forecast by Market Taxonomy
16.8.2.2.1. By Tests Type
16.8.2.2.2. By Infection Type
16.8.2.2.3. By End User
16.8.3. South Korea Market Analysis
16.8.3.1. Introduction
16.8.3.2. Market Analysis and Forecast by Market Taxonomy
16.8.3.2.1. By Tests Type
16.8.3.2.2. By Infection Type
16.8.3.3. By End User
17. Oceania Market 2017 to 2021 and Forecast 2022 to 2032
17.1. Introduction
17.2. Historical Market Size (US$ Million) Analysis Trend Analysis By Market Taxonomy, 2012 to 2021
17.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2022 to 2032
17.3.1. By Country
17.3.1.1. Australia
17.3.1.2. New Zealand
17.3.2. By Tests Type
17.3.3. By Infection Type
17.3.4. By End User
17.4. Market Attractiveness Analysis
17.4.1. By Country
17.4.2. By Tests Type
17.4.3. By Infection Type
17.4.4. By End User
17.5. Market Trends
17.6. Key Market Participants - Intensity Mapping
17.7. Drivers and Restraints - Impact Analysis
17.8. Country-Level Analysis & Forecast
17.8.1. Australia Market Analysis
17.8.1.1. Introduction
17.8.1.2. Market Analysis and Forecast by Market Taxonomy
17.8.1.2.1. By Tests Type
17.8.1.2.2. By Infection Type
17.8.1.2.3. By End User
17.8.2. New Zealand Market Analysis
17.8.2.1. Introduction
17.8.2.2. Market Analysis and Forecast by Market Taxonomy
17.8.2.2.1. By Tests Type
17.8.2.2.2. By Infection Type
17.8.2.2.3. By End User
18. Middle East and Africa (MEA) Market Analysis 2012 to 2021 and Forecast 2022 to 2032
18.1. Introduction
18.2. Historical Market Size (US$ Million) Analysis Trend Analysis By Market Taxonomy, 2012 to 2021
18.3. Current and Future Market Size (US$ Million) Analysis Forecast By Market Taxonomy, 2022 to 2032
18.3.1. By Country
18.3.1.1. GCC Countries
18.3.1.2. Turkey
18.3.1.3. South Africa
18.3.1.4. North Africa
18.3.2. By Tests Type
18.3.3. By Infection Type
18.3.4. By End User
18.4. Market Attractiveness Analysis
18.4.1. By Country
18.4.2. By Tests Type
18.4.3. By Infection Type
18.4.4. By End User
18.5. Market Trends
18.6. Key Market Participants - Intensity Mapping
18.7. Drivers and Restraints - Impact Analysis
18.8. Country-Level Analysis & Forecast
18.8.1. GCC Countries Market Analysis
18.8.1.1. Introduction
18.8.1.2. Market Analysis and Forecast by Market Taxonomy
18.8.1.2.1. By Tests Type
18.8.1.2.2. By Infection Type
18.8.1.2.3. By End User
18.8.2. Turkey Market Analysis
18.8.2.1. Introduction
18.8.2.2. Market Analysis and Forecast by Market Taxonomy
18.8.2.2.1. By Tests Type
18.8.2.2.2. By Infection Type
18.8.2.2.3. By End User
18.8.3. South Africa Market Analysis
18.8.3.1. Introduction
18.8.3.2. Market Analysis and Forecast by Market Taxonomy
18.8.3.2.1. By Tests Type
18.8.3.2.2. By Infection Type
18.8.3.2.3. By End User
18.8.4. North Africa Market Analysis
18.8.4.1. Introduction
18.8.4.2. Market Analysis and Forecast by Market Taxonomy
18.8.4.2.1. By Tests Type
18.8.4.2.2. By Infection Type
18.8.4.2.3. By End User
19. Market Structure Analysis
19.1. Market Analysis by Tier of Companies
19.2. Market Share Analysis of Top Players
19.3. Market Presence Analysis
20. Competition Analysis
20.1. Competition Dashboard
20.2. Competition Benchmarking
20.3. Competition Deep Dive
20.3.1. Abbott Laboratories
20.3.1.1. Overview
20.3.1.2. Product Portfolio
20.3.1.3. Fey Financials
20.3.1.4. Sales Footprint
20.3.1.5. Strategy Overview
20.3.2. bioMérieux SA,
20.3.2.1. Overview
20.3.2.2. Product Portfolio
20.3.2.3. Fey Financials
20.3.2.4. Sales Footprint
20.3.2.5. Strategy Overview
20.3.3. Bio-Rad Laboratories Inc.,
20.3.3.1. Overview
20.3.3.2. Product Portfolio
20.3.3.3. Fey Financials
20.3.3.4. Sales Footprint
20.3.3.5. Strategy Overview
20.3.4. Bruker Corporation,
20.3.4.1. Overview
20.3.4.2. Product Portfolio
20.3.4.3. Fey Financials
20.3.4.4. Sales Footprint
20.3.4.5. Strategy Overview
20.3.5. Danaher Corporation,
20.3.5.1. Overview
20.3.5.2. Product Portfolio
20.3.5.3. Fey Financials
20.3.5.4. Sales Footprint
20.3.5.5. Strategy Overview
20.3.6. Erba Mannheim,
20.3.6.1. Overview
20.3.6.2. Product Portfolio
20.3.6.3. Fey Financials
20.3.6.4. Sales Footprint
20.3.6.5. Strategy Overview
20.3.7. F. Hoffmann-La Roche AG,
20.3.7.1. Overview
20.3.7.2. Product Portfolio
20.3.7.3. Fey Financials
20.3.7.4. Sales Footprint
20.3.7.5. Strategy Overview
20.3.8. Luminex Corporation,
20.3.8.1. Overview
20.3.8.2. Product Portfolio
20.3.8.3. Fey Financials
20.3.8.4. Sales Footprint
20.3.8.5. Strategy Overview
20.3.9. Meridian Bioscience Inc.,
20.3.9.1. Overview
20.3.9.2. Product Portfolio
20.3.9.3. Fey Financials
20.3.9.4. Sales Footprint
20.3.9.5. Strategy Overview
20.3.10. Norgen Biotek Corp.,
20.3.10.1. Overview
20.3.10.2. Product Portfolio
20.3.10.3. Fey Financials
20.3.10.4. Sales Footprint
20.3.10.5. Strategy Overview
20.3.11. Omega Diagnostics Group Plc.,
20.3.11.1. Overview
20.3.11.2. Product Portfolio
20.3.11.3. Fey Financials
20.3.11.4. Sales Footprint
20.3.11.5. Strategy Overview
20.3.12. Qiagen N.V.,
20.3.12.1. Overview
20.3.12.2. Product Portfolio
20.3.12.3. Fey Financials
20.3.12.4. Sales Footprint
20.3.12.5. Strategy Overview
20.3.13. Quidel Corporation,
20.3.13.1. Overview
20.3.13.2. Product Portfolio
20.3.13.3. Fey Financials
20.3.13.4. Sales Footprint
20.3.13.5. Strategy Overview
20.3.14. Thermo Fisher Scientific Inc.
20.3.14.1. Overview
20.3.14.2. Product Portfolio
20.3.14.3. Fey Financials
20.3.14.4. Sales Footprint
20.3.14.5. Strategy Overview
21. Assumptions and Acronyms Used
22. Research Methodology
Explore Healthcare Insights
View Reports
Anti-microbial/Anti-fungal Tests Market
